The applications of microencapsulated formulation of gliclazide and bile acids in Type-1 diabetes mellitus
Embargo Lift Date
MetadataShow full item record
Gliclazide is used in Type 2 diabetes (T2D) to stimulate insulin production but it also has beneficial extra-pancreatic effects which make it potentially useful in T1D. In this thesis, gliclazide was formulated with different bile acids, to enhance its effects, and formed microcapsules were examined in-vitro and in-vivo. In-vitro examinations of the microcapsules included complete characterization of the microcapsules in terms of interactions between gliclazide and a primary bile acid (chenodeoxycholic acid), a secondary bile acid (taurocholic acid) and a tertiary bile acid (ursodeoxycholic acid), and in-vitro release of gliclazide from microcapsules, while in-vivo examination of the microcapsules included gliclazide absorption and hypoglycemic and antiinflammatory effects in a rat model of T1D.
Showing items related by title, author, creator and subject.
A comprehensive study of novel microcapsules incorporating gliclazide and a permeation enhancing bile acid: hypoglycemic effect in an animal model of Type-1 diabetesMathavan, Sangeetha; Chen-Tan, N.; Arfuso, Frank; Al-Salami, Hani (2015)Context: Gliclazide (G) is a commonly prescribed drug for Type 2 diabetes (T2D). In a recent study, we found that when G was combined with a primary bile acid, and gavaged to an animal model of Type 1 diabetes (T1D), it ...
High-Loading Dose of Microencapsulated Gliclazide Formulation Exerted a Hypoglycaemic Effect on Type 1 Diabetic Rats and Incorporation of a Primary Deconjugated Bile Acid, Diminished the Hypoglycaemic Antidiabetic EffectGolocorbin-Kon, S.; Calasan, J.; Milijasevic, B.; Vukmirovic, S.; Lalic-Popovic, M.; Mikov, M.; Al-Salami, Hani (2017)Background and objective: Gliclazide is a drug commonly used in type 2 diabetes mellitus. Recently, gliclazide has shown desirable pharmacological effects such as immunoregulatory and anti-clotting effects, which suggests ...
Stability and Release Kinetics of an Advanced Gliclazide-Cholic Acid Formulation: The Use of Artificial-Cell Microencapsulation in Slow Release Targeted Oral Delivery of AntidiabeticsMooranian, Armin; Negrulj, Rebecca; Mathavan, Sangeetha; Martinez, Jorge; Sciarretta, Jessica; Chen-Tan, Nigel; Mukkur, Trilochan; Mikov, Momir; Lalic-Popovic, M.; Stojancevic, M.; Golocorbin-Kon, S.; Al-Salami, Hani (2014)Introduction: In previous studies carried out in our laboratory, a bile acid (BA) formulation exerted a hypoglycaemic effect in a rat model of type-1 diabetes (T1D). When the antidiabetic drug gliclazide (G) was added to ...